All stock lists
Unlock the score InsiderBuyingOur analysisInhibrx Biosciences CEO Mark Lappe Buys $840,401 of Stock Across Five Form 4 FilingsChief Executive Mark Lappe picked up 9,940 shares of Inhibrx Biosciences on October 14th, 2026, at prices between $84.0707 and $85.76. The purchases were reported in five separate Form 4 filings.Oct 15, 2026InsiderBuyingOur analysisInhibrx Biosciences Director Kayyem Jon Faiz Buys $500,000 of Stock at $100 a ShareDirector Kayyem Jon Faiz picked up 5,000 shares of Inhibrx Biosciences on September 23rd, 2026, paying a flat $100 per share. The stock last traded at $99.61.Sep 28, 2026
Inhibrx Biosciences, Inc. (NASDAQ:INBX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
87.34
Insider Score
/ 100
INBX Insider Score
Inhibrx Biosciences, Inc. has a live Insider Score.
Scored on 20 qualifying trades from 3 insiders in the last 90 days.
Company News & Press Releases
No press releases on file for INBX.
Our Coverage
InsiderBuyingOur analysisInhibrx Biosciences CEO Mark Lappe Buys $840,401 of Stock Across Five Form 4 FilingsChief Executive Mark Lappe picked up 9,940 shares of Inhibrx Biosciences on October 14th, 2026, at prices between $84.0707 and $85.76. The purchases were reported in five separate Form 4 filings.Oct 15, 2026InsiderBuyingOur analysisInhibrx Biosciences Director Kayyem Jon Faiz Buys $500,000 of Stock at $100 a ShareDirector Kayyem Jon Faiz picked up 5,000 shares of Inhibrx Biosciences on September 23rd, 2026, paying a flat $100 per share. The stock last traded at $99.61.Sep 28, 2026Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.